Citius Oncology Announces Expansion of Institutional Orders for LYMPHIR®

What Happened Citius Oncology, Inc. (CTOR) filed a Form 8‑K on August 5, 2026, to furnish a press release announcing an update on the expanding base of institutional accounts ordering its product LYMPHIR®. The press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Filing date: August 5, 2026 (Form 8‑K, Item 8.01 — Other Events).
• Subject: company update on expanding institutional accounts ordering LYMPHIR®.
• Press release was furnished as Exhibit 99.1 to the 8‑K.
• The 8‑K did not include financial figures, order quantities, or revenue impact.

Why It Matters An announced expansion in institutional accounts ordering LYMPHIR® is a commercial update that investors can treat as an indication of growing adoption of the product. Because the filing provides no sales or revenue figures, investors should look for future disclosures (quarterly results, revenue reports, or subsequent press releases) for quantified impact on earnings or guidance.